Rossari Biotech Limited has released its Consolidated financial results for the fiscal year ending on March 31, 2023.
Financial Results (Q4 FY2023) – QoQ Comparison
During the period ending March 31, 2023, the company reported a total income of Rs 409.272 crores, compared to Rs 390.383 crores during the period ending December 31, 2022.
The company’s net profit / (loss) for the period ending March 31, 2023 was Rs. 28,979 crores, compared to Rs. 25,681 crores for the period ending December 31, 2022.
For the period ending March 31, 2023, the company reported EPS of Rs 5.24, compared to Rs 4.63 for the period ending December 31, 2022.
| Financials | Q4 FY2023 | Q3 FY2023 | % Change |
| Total Income | ₹409.272 crs | ₹390.383 crs |  4.84% |
| Net Profit | ₹28.979 crs | ₹25.681 crs | 12.84% |
| EPS | ₹5.24 | ₹4.63 | 13.17% |
Financial Results (Q4 FY2023) – Comparison Year-Over-Year
During the period ending March 31, 2023, the company reported a total income of Rs.409.272 crores, compared to Rs.440.904 crores during the period ending March 31, 2022.
The company’s net profit / (loss) for the period ending March 31, 2023 was Rs.28.979 crores, compared to Rs.24.081 crores for the period ending March 31, 2022.
For the period ending March 31, 2023, the company reported EPS of Rs.5.24, compared to Rs.4.35 for the period ending March 31, 2022.
| Financials | Q4 FY2023 | Q4 FY2022 | % Change |
| Total Income | ₹409.272 crs | ₹440.904 crs |  -7.17% |
| Net Profit | ₹28.979 crs | ₹24.081 crs | 20.34% |
| EPS | ₹5.24 | ₹4.35 | 20.46% |
Financial Results (Year Ending FY2023) – Comparison to Prior Year
The company’s total revenue for the fiscal year ending March 31, 2023 was Rs. 1,661,365 crores, compared to Rs. 1,494,97 crores for the fiscal year ending March 31, 2022.
The company’s net profit/(loss) for the fiscal year ending on March 31, 2023 was Rs.107.257 crores, compared to Rs.97.674 crores for the fiscal year ending on March 31, 2022.
The company’s EPS for the fiscal year ending March 31, 2023 was Rs.19.38, compared to Rs.17.70 for the fiscal year ending March 31, 2022.
| Financials | Year Ended FY2023 | Year Ended FY2022 | % Change |
| Total Income | ₹1661.365 crs | ₹1494.97 crs | 11.13% |
| Net Profit | ₹107.257 crs | ₹97.674 crs | 9.81% |
| EPS | ₹19.38 | ₹17.70 | 9.49% |
Last on the BSE, shares of Rossari Biotech Limited were priced at Rs 688.40, up from the previous close of Rs 685. The total number of shares traded in excess of 1147 transactions was 10,676.
The stock’s intraday high was 696.30 rupees and its intraday low was 677.65 rupees. The daily net sales amounted to Rs. 7327846.
